Xenon scores up to $646m in Genentech pain deal
This article was originally published in Scrip
Vancouver-based Xenon Pharmaceuticals stands to receive up to $646 million in milestones under a deal it has signed with Roche's Genentech for the discovery and development of compounds to treat pain and companion diagnostics. The deal also includes an undisclosed upfront payment and research funding, plus royalties on eventual sales.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.